Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-02-24 Purchase |
2023-02-28 5:33 pm |
GLYCOMIMETICS INC | GLYC | Invus Public Equities L.P. Artal International S.C.A. Artal International Management S.A. Artal Group S.A. Westend S.A. Wittouck Amaury Stichting Administratiekantoor Westend Invus Public Equities Advisors LLC 10% Owner |
100,000 | $1.7 | $170,000 | 8,589,064 (Direct) |
View |
| 2023-02-21 Purchase |
2023-02-23 6:23 pm |
GLYCOMIMETICS INC | GLYC | Invus Public Equities L.P. Artal International S.C.A. Artal International Management S.A. Artal Group S.A. Westend S.A. Wittouck Amaury Stichting Administratiekantoor Westend Invus Public Equities Advisors LLC 10% Owner |
400,000 | $1.7806 | $712,255 | 8,489,064 (Direct) |
View |
| 2023-02-15 Purchase |
2023-02-17 5:29 pm |
GLYCOMIMETICS INC | GLYC | Invus Public Equities L.P. Artal International S.C.A. Artal International Management S.A. Artal Group S.A. Westend S.A. Wittouck Amaury Stichting Administratiekantoor Westend Invus Public Equities Advisors LLC 10% Owner |
1,515,266 | $1.9983 | $3,027,929 | 8,089,064 (Direct) |
View |
| 2023-02-09 Purchase |
2023-02-13 5:45 pm |
GLYCOMIMETICS INC | GLYC | Invus Public Equities L.P. Artal International S.C.A. Artal International Management S.A. Artal Group S.A. Westend S.A. Wittouck Amaury Stichting Administratiekantoor Westend Invus Public Equities Advisors LLC 10% Owner |
11,451 | $3.2419 | $37,123 | 6,573,798 (Direct) |
View |
| 2023-01-25 Sale |
2023-01-27 5:15 pm |
GLYCOMIMETICS INC | GLYC | SANDELL SCOTT D 10% Owner |
3,652,016 | $3.1447 | $11,484,515 | 2,237,196 (Indirect) |
View |
| 2023-01-05 Sale |
2023-01-06 6:35 pm |
GLYCOMIMETICS INC | GLYC | SANDELL SCOTT D 10% Owner |
71,362 | $2.7586 | $196,859 | 3,881,933 (Indirect) |
View |
| 2022-12-30 Sale |
2023-01-04 5:26 pm |
GLYCOMIMETICS INC | GLYC | SANDELL SCOTT D 10% Owner |
398,133 | $2.9786 | $1,185,886 | 3,914,072 (Indirect) |
View |
| 2022-12-22 Purchase |
2022-12-27 6:41 pm |
GLYCOMIMETICS INC | GLYC | Rock Edwin Chief Medical Officer |
110,000 | $2.25 | $247,500 | 310,000 (Direct) |
View |
| 2022-11-17 Purchase |
2022-11-18 4:01 pm |
GLYCOMIMETICS INC | GLYC | JUNIUS DANIEL M Director |
20,000 | $1.87 | $37,400 | 63,250 (Direct) |
View |
| 2022-11-14 Purchase |
2022-11-16 4:26 pm |
GLYCOMIMETICS INC | GLYC | Rock Edwin Chief Medical Officer |
200,000 | $1.545 | $309,000 | 200,000 (Direct) |
View |
| 2022-11-11 Purchase |
2022-11-14 4:14 pm |
GLYCOMIMETICS INC | GLYC | PEARSON TIMOTHY R Director |
19,400 | $1.29 | $25,026 | 24,650 (Direct) |
View |
| 2022-11-11 Purchase |
2022-11-14 4:13 pm |
GLYCOMIMETICS INC | GLYC | Semerjian Harout Chief Executive Officer |
25,000 | $1.29 | $32,250 | 25,000 (Direct) |
View |
| 2022-11-11 Purchase |
2022-11-14 4:13 pm |
GLYCOMIMETICS INC | GLYC | Hahn Brian M. SVP Finance, CFO |
20,000 | $1.06 | $21,200 | 56,843 (Direct) |
View |
| 2022-11-11 Purchase |
2022-11-14 4:11 pm |
GLYCOMIMETICS INC | GLYC | Magnani John L. SVP of Research, CSO |
45,045 | $1.17 | $52,703 | 370,923 (Indirect Direct) |
View |
| 2022-11-11 Purchase |
2022-11-14 4:04 pm |
GLYCOMIMETICS INC | GLYC | Girard Armand SVP, Chief Business Officer |
6,500 | $1.05 | $6,825 | 29,161 (Direct) |
View |
| 2022-03-09 Sale |
2022-03-10 5:06 pm |
GLYCOMIMETICS INC | GLYC | Magnani John L. SVP of Research, CSO |
3,227 | $1.09 | $3,517 | 325,878 (Indirect Direct) |
View |
| 2022-03-09 Sale |
2022-03-10 5:05 pm |
GLYCOMIMETICS INC | GLYC | Girard Armand SVP, Chief Business Officer |
2,339 | $1.09 | $2,550 | 22,661 (Direct) |
View |
| 2022-03-09 Sale |
2022-03-10 5:03 pm |
GLYCOMIMETICS INC | GLYC | Hahn Brian M. SVP Finance, CFO |
2,917 | $1.09 | $3,180 | 36,843 (Direct) |
View |
| 2021-11-16 Purchase |
2021-11-18 4:05 pm |
GLYCOMIMETICS INC | GLYC | Andrews Patricia S Director |
40,000 | $2.05 | $82,000 | 45,250 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
Ownership |
2023-03-31 4:36 pm |
N/A N/A |
GLYCOMIMETICS INC | GLYC | Rath Chinmaya SVP and Chief Business Officer |
0 | $0 | 311,178 (Direct) |
View |
Ownership |
2023-03-31 4:34 pm |
N/A N/A |
GLYCOMIMETICS INC | GLYC | Johnson Bruce S SVP & Chief Commercial Officer |
0 | $0 | 560,480 (Direct) |
View |
Ownership |
2023-02-13 5:40 pm |
N/A N/A |
GLYCOMIMETICS INC | GLYC | Invus Public Equities L.P. Artal International S.C.A. Artal International Management S.A. Artal Group S.A. Westend S.A. Wittouck Amaury Stichting Administratiekantoor Westend Invus Public Equities Advisors LLC 10% Owner |
0 | $0 | 6,562,347 (Direct) |
View |
| 2022-02-15 Ownership |
2023-02-06 4:13 pm |
N/A N/A |
GLYCOMIMETICS INC | GLYC | King Rachel K. Director |
19,141 | $0 | 646,597 (Direct) |
View |
Ownership |
2023-02-06 4:13 pm |
N/A N/A |
GLYCOMIMETICS INC | GLYC | King Rachel K. Director |
0 | $0 | 646,597 (Indirect) |
View |
| 2023-01-27 Exercise |
2023-01-30 4:13 pm |
N/A N/A |
GLYCOMIMETICS INC | GLYC | Koenig Scott Director |
10,500 | $2.55 | 15,750 (Direct) |
View |
| 2023-01-27 Exercise |
2023-01-30 4:13 pm |
N/A 2031-05-17 |
GLYCOMIMETICS INC | GLYC | Koenig Scott Director |
10,500 | $0 | 15,750 (Direct) |
View |
| 2023-01-19 Option Award |
2023-01-20 4:08 pm |
N/A 2033-01-18 |
GLYCOMIMETICS INC | GLYC | Hahn Brian M. SVP Finance, CFO |
246,300 | $0 | 246,300 (Direct) |
View |
| 2023-01-19 Option Award |
2023-01-20 4:04 pm |
N/A 2033-01-18 |
GLYCOMIMETICS INC | GLYC | Semerjian Harout Chief Executive Officer |
651,200 | $0 | 651,200 (Direct) |
View |
| 2023-01-19 Option Award |
2023-01-20 4:02 pm |
N/A 2033-01-18 |
GLYCOMIMETICS INC | GLYC | Rock Edwin Chief Medical Officer |
244,800 | $0 | 244,800 (Direct) |
View |
| 2022-09-02 Option Award |
2022-09-07 4:10 pm |
N/A 2032-09-01 |
GLYCOMIMETICS INC | GLYC | Rock Edwin Chief Medical Officer |
200,000 | $0 | 200,000 (Direct) |
View |
Ownership |
2022-09-07 4:08 pm |
N/A N/A |
GLYCOMIMETICS INC | GLYC | Rock Edwin Chief Medical Officer |
0 | $0 | 0 (Direct) |
View |
| 2022-05-18 Option Award |
2022-05-20 4:20 pm |
N/A 2032-05-17 |
GLYCOMIMETICS INC | GLYC | PEARSON TIMOTHY R Director |
21,000 | $0 | 21,000 (Direct) |
View |
| 2022-05-18 Option Award |
2022-05-20 4:19 pm |
N/A 2032-05-17 |
GLYCOMIMETICS INC | GLYC | Koenig Scott Director |
21,000 | $0 | 21,000 (Direct) |
View |
| 2022-05-18 Option Award |
2022-05-20 4:16 pm |
N/A 2032-05-17 |
GLYCOMIMETICS INC | GLYC | King Rachel K. Director |
21,000 | $0 | 21,000 (Direct) |
View |
| 2022-05-18 Option Award |
2022-05-20 4:13 pm |
N/A 2032-05-17 |
GLYCOMIMETICS INC | GLYC | JUNIUS DANIEL M Director |
21,000 | $0 | 21,000 (Direct) |
View |
| 2022-05-18 Option Award |
2022-05-20 4:10 pm |
N/A 2032-05-17 |
GLYCOMIMETICS INC | GLYC | Jackson Scott Thomas Director |
21,000 | $0 | 21,000 (Direct) |
View |
| 2022-05-18 Option Award |
2022-05-20 4:08 pm |
N/A 2032-05-17 |
GLYCOMIMETICS INC | GLYC | Goldberg Mark Alan Director |
21,000 | $0 | 21,000 (Direct) |
View |
| 2022-05-18 Option Award |
2022-05-20 4:06 pm |
N/A 2032-05-17 |
GLYCOMIMETICS INC | GLYC | Andrews Patricia S Director |
21,000 | $0 | 21,000 (Direct) |
View |
| 2022-01-21 Option Award |
2022-01-25 9:02 pm |
N/A 2032-01-20 |
GLYCOMIMETICS INC | GLYC | Girard Armand SVP, Chief Business Officer |
192,400 | $0 | 192,400 (Direct) |
View |
| 2022-01-21 Option Award |
2022-01-25 9:01 pm |
N/A 2032-01-20 |
GLYCOMIMETICS INC | GLYC | Magnani John L. SVP of Research, CSO |
125,000 | $0 | 125,000 (Direct) |
View |
| 2022-01-21 Option Award |
2022-01-25 8:59 pm |
N/A 2032-01-20 |
GLYCOMIMETICS INC | GLYC | Hahn Brian M. SVP Finance, CFO |
212,400 | $0 | 212,400 (Direct) |
View |
| 2022-01-21 Option Award |
2022-01-25 8:58 pm |
N/A 2032-01-20 |
GLYCOMIMETICS INC | GLYC | Semerjian Harout Chief Executive Officer |
423,500 | $0 | 423,500 (Direct) |
View |